Concourse Financial Group Securities, Inc. Rezolute, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $0
  • Q2 2025
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
100.0%
Previous 100.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$2.47 - $4.46 $0 - $0
0 New
0 $0
Q1 2025

May 14, 2025
BUY
$2.73 - $5.57 $0 - $0
0 New
0 $0
Q4 2024

Feb 13, 2025
BUY
$4.08 - $5.96 $0 - $0
0 New
0 $0
Q3 2024

Oct 10, 2024
BUY
$4.13 - $5.31 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024
BUY
$2.29 - $5.79 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024
BUY
$0.95 - $2.55 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$0.74 - $1.24 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$1.32 - $2.1 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$1.32 - $2.1 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$1.75 - $2.33 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$1.79 - $2.87 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$1.38 - $2.84 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$2.19 - $3.49 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$2.6 - $3.85 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$2.27 - $5.1 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$4.21 - $7.61 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$7.45 - $13.66 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$6.11 - $15.99 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$6.83 - $17.3 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$11.99 - $24.05 $0 - $0
0 New
0 $0

Others Institutions Holding RZLT

# of Institutions
105
Shares Held
60.1M
Call Options Held
713K
Put Options Held
19K
View Full List

About Rezolute, Inc.

RZLT Quotes by TradingView
  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $418M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email